Disquiet is growing over the way that Oxford university and AstraZeneca have handled the early readout from trials of their coronavirus vaccine, which much of the developing world may rely on to emerge from the pandemic.
The results were hailed a success for showing an average efficacy of 70 per cent — a figure reached by pooling the results from cohorts on two different dosing regimens.
A month apart, one set of participants received two identical doses, while the other group received a half-dose, and then a full dose. The efficacy for the first, larger group was 62 per cent. In the second subgroup, it was 90 per cent.
您已閱讀11%（625字），剩余89%（5145字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。